Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 9/20 | 0.58 |
| ▸ | TNKS | O95271 | 3/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484023 | 0.85 | TNKS (0.56) | TNKSMAP4K1FGFR3HRH4 | |
| SCHEMBL1484208 | 0.79 | TNKS (0.59) | TNKSFGFR3HRH4 | |
| SCHEMBL1484244 | 0.79 | CYP19A1 (0.43) | PRMT5NTRK1ACHEMAOB | |
| SCHEMBL1422528 | 0.79 | NTRK1 (0.41) | PRMT5NTRK1FGFR3ACHEMAOB | |
| SCHEMBL13577843 | 0.78 | TNKS (0.58) | TNKSFGFR3HRH4ALK | |
| SCHEMBL1483676 | 0.78 | TNKS (0.58) | TNKSNTRK1FGFR3HRH4ALK | |
| SCHEMBL1484242 | 0.78 | ALOX5 (0.46) | PRMT5ACHEMAOB | |
| SCHEMBL1484021 | 0.77 | TNKS (0.56) | TNKSFGFR3HRH4 | |
| SCHEMBL4890810 | 0.76 | ALOX5 (0.57) | PRMT5ACHEMAOB | |
| SCHEMBL1484602 | 0.76 | TNKS (0.55) | TNKSMAP4K1FGFR3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | claimed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| WO-2009155024-A1 | NOVEL SUBSTITUTED INDOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | APP, BACE1, PSEN1 | PRMT5 1274/4885TNKS 3337/4885NTRK1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.